{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.9","upperLimit":"14.5","value":"7.7"},{"groupId":"OG001","lowerLimit":"2.9","upperLimit":"7.0","value":"5.6"},{"groupId":"OG002","lowerLimit":"7.9","upperLimit":"18.7","value":"8.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"5"}],"units":"Participants"}],"description":"Progression free survival is defined as the interval of time (in months) between the date of first dose and the earlier of the date of disease progression and date of death due to any cause. Confidence intervals were estimated using Brookmeyer Crowley method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants were administered twice daily (BID) oral dose of 20 mg GSK525762.","id":"OG000","title":"Part 1: GSK525762 20 mg BID"},{"description":"Participants were administered twice daily oral dose of 30 mg GSK525762.","id":"OG001","title":"Part 1: GSK525762 30 mg BID"},{"description":"Participants were administered twice daily oral dose of 40 mg GSK525762.","id":"OG002","title":"Part 1: GSK525762 40 mg BID"}],"paramType":"MEDIAN","populationDescription":"All Treated Population","reportingStatus":"POSTED","timeFrame":"Median of 1.41 months of drug exposure","title":"Progression Free Survival-Part 1 BID","type":"SECONDARY","unitOfMeasure":"Months"}